Previously, we proposed using an interpolated average CT (IACT) method for attenuation correction (AC) in positron emission tomography (PET), which is a good, low-dose approximation of cine average CT (CACT) to reduce misalignments and improve quantification in PET/CT. This study aims to evaluate the performance of IACT for different motion amplitudes. We used the digital four-dimensional (4-D) extended cardiac-torso phantom (XCAT) to simulate maximum of 2, 3, and 4 cm respiratory motions. The respiratory cycle was divided into 13 phases, with average activity and attenuation maps to represent 1 8Ffluorodeoxyglucose (1 8F-FDG) distributions with average respiratory motions and CACT, respectively. The end-inspiration, endexpiration, and midrespiratory phases of the XCAT attenuation maps represented three different helical CTs (i.e., HCT-1, HCT-5, and HCT-8). The IACTs were generated using: 1) 2 extreme + 11 interpolated phases (IACT2 o ); 2) 2 phases right after the extreme phases + 11 interpolated phases (IACT2 s ); 3) 4 original + 9 interpolated phases (IACT4 o ). A spherical lesion with a targetto-background ratio (TBR) of 4:1 and a diameter of 25 mm was placed in the base of right lung. The noise-free and noisy sinograms with attenuation modeling were generated and reconstructed with different noise-free and noisy AC maps (CACT, HCTs, and IACTs) by Software for Tomographic Image Reconstruction, respectively, using ordered subset expectation maximization(OS-EM) with up to 300 updates. Normalized mean-square error, mutual information (MI), TBR, image profile, and noise-contrast tradeoff were analyzed. The PET reconstructed images with AC using CACT showed least difference as compared to the original phantom, followed by IACT4 o , IACT2 o , IACT2 s , HCT-5, HCT-8, and HCT-1. Significant artifacts were observed in the reconstructed images using HCTs for AC. The MI differences between IACT2 o and IACT4 o /CACT were <0.41% and <2.17%, respectively. With a slight misplacement of the two extreme phases, IACT2 s was still comparable to IACT2 o with MI difference of <2.23%. The IACT is a robust and accurate low-dose alternate to CACT.